A new study indicates that glucagon-like peptide 1 receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), widely used for diabetes and obesity, could also help treat opioid use disorder (OUD) and alcohol use disorder (AUD). Researchers analyzed real-world data from over 1 million adults with a history of OUD or AUD. They found that those taking GLP-1 RAs had a 40% lower risk of opioid overdose and a 50% lower risk of alcohol intoxication compared to those not taking these medications.
The findings provide foundational evidence of a potential link between GLP-1 RAs and reduced substance misuse, suggesting these medications could be repurposed as novel treatments for addiction. The researchers, led by Dr. Fares Qeadan from Loyola University Chicago, recommend further studies to explore their therapeutic potential in addressing OUD and AUD.
The protective effect of GLP-1 RAs against opioid overdose and alcohol intoxication was maintained in patients with comorbid conditions such as type 2 diabetes and obesity.
Matt Field, a psychology professor from the University of Sheffield, stated that the findings align with previous research, including animal studies, suggesting that GLP-1 RAs could potentially be used to treat addiction in the future.
